ATE408414T1 - Glp 1 exendin 4 peptidanaloga und deren verwendungen - Google Patents

Glp 1 exendin 4 peptidanaloga und deren verwendungen

Info

Publication number: ATE408414T1
Authority: AT; Austria
Prior art keywords: exendin; glp; polypeptide; relates; peptide analogues
Prior art date: 2001-07-31

Application number

AT02748271T

Other languages

English (en)

Inventor

Nigel Greig

Josephine Egan

Maire Doyle

Harold Holloway

Tracy Perry

Original Assignee

Us Gov Health & Human Serv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-31

Filing date

2002-07-30

Publication date

2008-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23196575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE408414(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-07-30 Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv

2008-10-15 Application granted granted Critical

2008-10-15 Publication of ATE408414T1 publication Critical patent/ATE408414T1/de

Links

101800000224 Glucagon-like peptide 1 Proteins 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 5
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
108010011459 Exenatide Proteins 0.000 abstract 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 3
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 3
229960001519 exenatide Drugs 0.000 abstract 3
230000002473 insulinotropic effect Effects 0.000 abstract 3
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 2
102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 2
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000000508 neurotrophic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)

AT02748271T 2001-07-31 2002-07-30 Glp 1 exendin 4 peptidanaloga und deren verwendungen ATE408414T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30907601P	2001-07-31	2001-07-31

Publications (1)

Publication Number	Publication Date
ATE408414T1 true ATE408414T1 (de)	2008-10-15

Family

ID=23196575

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT02748271T ATE408414T1 (de)	2001-07-31	2002-07-30	Glp 1 exendin 4 peptidanaloga und deren verwendungen
AT08162544T ATE536881T1 (de)	2001-07-31	2002-07-30	Glp-1, exendin-4, peptid-analoga und verwendungen davon

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT08162544T ATE536881T1 (de)	2001-07-31	2002-07-30	Glp-1, exendin-4, peptid-analoga und verwendungen davon

Country Status (8)

Country	Link
US (4)	US7576050B2 (de)
EP (3)	EP2275117B1 (de)
JP (3)	JP2005501058A (de)
AT (2)	ATE408414T1 (de)
AU (2)	AU2002317599B2 (de)
CA (1)	CA2455963C (de)
DE (1)	DE60228972D1 (de)
WO (1)	WO2003011892A2 (de)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20050272652A1 (en) *	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP2213743A1 (de)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albuminfusionsproteine
JP4716641B2 (ja) *	2000-06-16	2011-07-06	イーライリリーアンドカンパニー	グルカゴン様ペプチド−１類似体
ATE408414T1 (de)	2001-07-31	2008-10-15	Us Gov Health & Human Serv	Glp 1 exendin 4 peptidanaloga und deren verwendungen
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2003200839B2 (en) *	2002-01-08	2008-12-11	Eli Lilly And Company	Extended glucagon-like peptide-1 analogs
GB0205693D0 (en) *	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006520818A (ja) *	2003-03-19	2006-09-14	イーライリリーアンドカンパニー	ポリエチレングリコール結合ｇｌｐ−１化合物
CA2518465A1 (en)	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
ATE549028T1 (de) *	2003-05-15	2012-03-15	Tufts College	Stabile analoga von glp-1
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7329725B1 (en)	2003-10-29	2008-02-12	Nastech Pharmaceutical Company Inc.	Phage displayed Trp cage ligands
AU2005203925A1 (en)	2004-01-08	2005-07-21	Theratechnologies Inc.	Glucagon-Like Peptide-1 analogs with long duration of action
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
US8603969B2 (en)	2004-02-11	2013-12-10	Amylin Pharmaceuticals, Llc	Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2006037810A2 (en)	2004-10-07	2006-04-13	Novo Nordisk A/S	Protracted glp-1 compounds
US8030273B2 (en)	2004-10-07	2011-10-04	Novo Nordisk A/S	Protracted exendin-4 compounds
CA2599594A1 (en) *	2004-12-24	2006-07-13	Amylin Pharmaceuticals, Inc.	Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
KR20070115947A (ko)	2005-02-11	2007-12-06	아밀린 파마슈티칼스, 인크.	선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
WO2007022123A2 (en) *	2005-08-11	2007-02-22	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
WO2007017892A2 (en) *	2005-05-05	2007-02-15	Cadila Healthcare Limited	Novel compounds as glp-i agonists
CN100429227C (zh)	2005-06-29	2008-10-29	常州制药厂有限公司	Exendin4多肽片段
MX2008002028A (es) *	2005-08-11	2008-03-27	Amylin Pharmaceuticals Inc	Polipeptidos hibridos con propiedades de seleccion.
US8318668B2 (en)	2005-09-08	2012-11-27	Trustees Of Tufts College	Stabilized GLP-1 analogs
CA2622069A1 (en) *	2005-09-08	2007-03-15	Uutech Limited	Treatment of diabetes related obesity
CA2623412A1 (en) *	2005-09-08	2007-03-15	Uutech Limited	Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
MY147393A (en)	2005-09-14	2012-11-30	Takeda Pharmaceutical	Administration of dipeptidyl peptidase inhibitors
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
DE602005017628D1 (de)	2005-09-22	2009-12-24	Biocompatibles Uk Ltd	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
CA2913805A1 (en)	2005-11-07	2007-05-18	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2009532422A (ja) *	2006-04-03	2009-09-10	ノボ・ノルデイスク・エー／エス	Ｇｌｐ−１ペプチドアゴニスト
JP2009534423A (ja) *	2006-04-20	2009-09-24	アムジェンインコーポレイテッド	Ｇｌｐ−１化合物
EP1854455B1 (de)	2006-05-10	2009-10-07	Biocompatibles UK Limited	GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
KR101106510B1 (ko)	2006-05-30	2012-01-20	인타르시아 세라퓨틱스 인코포레이티드	투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (de)	2006-08-09	2013-05-22	Intarcia Therapeutics, Inc	Osmotisches Verabreichungssystem mit Kolbenanordnung
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
RU2477286C2 (ru)	2007-01-05	2013-03-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
RU2413528C2 (ru)	2007-01-18	2011-03-10	Открытое Акционерное Общество "Валента Фармацевтика"	Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
CA2677932A1 (en)	2007-02-15	2008-08-21	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
EP1972349A1 (de) *	2007-03-21	2008-09-24	Biocompatibles UK Limited	Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) *	2007-03-27	2008-10-01	Biocompatibles UK Limited	Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
WO2008133908A2 (en)	2007-04-23	2008-11-06	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
US20100292133A1 (en) *	2007-09-05	2010-11-18	Novo Nordisk A/S	Truncated glp-1 derivaties and their therapeutical use
EP2190872B1 (de)	2007-09-05	2018-03-14	Novo Nordisk A/S	Glucagon-like peptid-1-derivate und ihre pharmazeutische verwendung
WO2009030771A1 (en) *	2007-09-05	2009-03-12	Novo Nordisk A/S	Peptides derivatized with a-b-c-d- and their therapeutical use
GB0717399D0 (en)	2007-09-07	2007-10-17	Uutech Ltd	Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
GB0717388D0 (en)	2007-09-07	2007-10-17	Uutech Ltd	Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
ES2509883T3 (es)	2007-10-30	2014-10-20	Indiana University Research And Technology Corporation	Antagonistas de glucagón
MX2010004298A (es)	2007-10-30	2010-05-03	Univ Indiana Res & Tech Corp	Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009149148A2 (en) *	2008-06-03	2009-12-10	Trustees Of Tufts College	Long-acting glp-1 derivatives, and methods of treating cardiac dysfunction
AR072160A1 (es)	2008-06-17	2010-08-11	Univ Indiana Res & Tech Corp	Co-agonistas del receptor de glucagon/glp-1
US8450270B2 (en)	2008-06-17	2013-05-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CN102105159B (zh)	2008-06-17	2015-07-08	印第安纳大学研究及科技有限公司	基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
PE20120332A1 (es)	2008-12-19	2012-04-14	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida
BRPI0923853A2 (pt) *	2008-12-29	2016-01-12	Panacea Biotec Ltd	análogos de gpl-1 e usos dos mesmos.
WO2010120476A2 (en) *	2009-04-01	2010-10-21	Amylin Pharmaceuticals, Inc.	N-terminus conformationally constrained glp-1 receptor agonist compounds
US8992886B2 (en) *	2009-04-06	2015-03-31	Board Of Regents, The University Of Texas System	Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
EP2443146B1 (de)	2009-06-16	2016-10-05	Indiana University Research And Technology Corporation	Gip-rezeptor-aktive glucagon-verbindungen
US20120148586A1 (en) *	2009-08-27	2012-06-14	Joyce Ching Tsu Chou	Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
RU2547990C2 (ru)	2009-09-28	2015-04-10	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
US8703701B2 (en)	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
KR20120123443A (ko)	2010-01-27	2012-11-08	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
JP6050746B2 (ja)	2010-05-13	2016-12-21	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションIndiana University Research And Technology Corporation	Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
MX2012013001A (es)	2010-05-13	2013-02-26	Univ Indiana Res & Tech Corp	Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
EP2588126A4 (de)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	Amidbasierte glucagon-superfamilien-peptid-prodrugs
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9023986B2 (en)	2010-10-25	2015-05-05	Hoffmann-La Roche Inc.	Glucose-dependent insulinotropic peptide analogs
SI2651398T1 (en)	2010-12-16	2018-04-30	Novo Nordisk A/S	SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
US8507428B2 (en)	2010-12-22	2013-08-13	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
EP2668951B9 (de)	2011-01-25	2017-03-15	Viviabiotech, S.L.	1,2,4-oxadiazolderivate als wirkstoffe zur modulation des glp-1-peptidrezeptors
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PL2696687T3 (pl)	2011-04-12	2017-06-30	Novo Nordisk A/S	Pochodne podwójnie acylowanej GLP-1
US9511103B2 (en)	2011-04-20	2016-12-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RS56173B1 (sr)	2011-06-22	2017-11-30	Univ Indiana Res & Tech Corp	Koagonisti receptora za glukagon/glp-1 receptora
KR20140043793A (ko)	2011-06-22	2014-04-10	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	글루카곤/glp-1 수용체 공동-작용물질
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) *	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP6324315B2 (ja)	2011-11-17	2018-05-16	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
US9388212B2 (en)	2013-02-21	2016-07-12	Chemical & Biopharmaceutical Laboratories Of Patras S.A.	Solid phase peptide synthesis via side chain attachment
PT2827845T (pt)	2012-03-22	2019-03-29	Novo Nordisk As	Composições compreendendo um agente de entrega e sua preparação
HRP20181447T1 (hr)	2012-03-22	2018-11-02	Novo Nordisk A/S	Pripravci glp-1 peptida i njihova priprava
JP6517690B2 (ja)	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
CN104583232B (zh)	2012-06-21	2018-04-13	印第安纳大学研究及科技有限公司	展现gip受体活性的胰高血糖素类似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506391A (ja) *	2012-12-06	2016-03-03	ステルスペプチドズインターナショナルインコーポレイテッド	ペプチド治療薬およびその使用方法
JP2016503046A (ja) *	2012-12-19	2016-02-01	ノヴォノルディスクアー／エス	コレステロール流出活性を有する新規ｇｌｐ−１受容体アゴニスト
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
JP6382488B2 (ja) *	2013-02-21	2018-08-29	ケミカルアンドバイオファーマシューティカルラボラトリーズオブパトラエス．エー．	側鎖結合を介する固相ペプチド合成
KR102272671B1 (ko)	2013-05-02	2021-07-06	노보 노르디스크 에이/에스	Glp-1 화합물의 경구 투여
CA2929555A1 (en)	2013-11-08	2015-05-14	Baylor Research Institute	Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
US10626156B2 (en)	2013-12-06	2020-04-21	Jie Han	Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (de)	2013-12-13	2018-02-07	Sanofi	Duale glp-1/gip-rezeptoragonisten
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
GB201415598D0 (en)	2014-09-03	2014-10-15	Univ Birmingham	Elavated Itercranial Pressure Treatment
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3229828B1 (de)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
PE20171154A1 (es)	2014-12-30	2017-08-16	Hanmi Pharm Ind Co Ltd	Derivados de glucagon con estabilidad mejorada
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
US10993993B2 (en)	2015-05-28	2021-05-04	Immunoforge Co., Ltd.	Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
KR101661332B1 (ko) *	2015-05-28	2016-09-29	(의료)길의료재단	글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
RU2730996C2 (ru)	2015-06-03	2020-08-26	Интарсия Терапьютикс, Инк.	Системы установки и извлечения имплантата
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EP4523705A3 (de)	2015-06-30	2025-06-11	Hanmi Pharm. Co., Ltd.	Glucagonderivat und zusammensetzung mit einem langwirkenden konjugat davon
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN108697768B (zh) *	2015-12-23	2022-07-22	约翰霍普金斯大学	长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
SG11201805586SA (en)	2015-12-31	2018-07-30	Hanmi Pharmaceutical Co Ltd	Triple glucagon/glp-1/gip receptor agonist
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
EP3479841A4 (de)	2016-06-29	2020-03-04	Hanmi Pharm. Co., Ltd.	Glucagonderivat, konjugat davon, zusammensetzung damit und therapeutische verwendung davon
CA3040906A1 (en)	2016-10-20	2018-04-26	Peptron, Inc.	Methods of delivering a neuroprotective polypeptide to the central nervous system
JP7286542B2 (ja)	2017-01-03	2023-06-05	インターシアセラピューティクス，インコーポレイティド	Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
JP6898518B2 (ja)	2018-02-02	2021-07-07	ノヴォノルディスクアー／エス	Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
CN110452952B (zh) *	2018-05-08	2024-01-16	宜昌东阳光长江药业股份有限公司	一种glp-1类似物生物活性的检测方法
KR101921085B1 (ko)	2018-05-21	2018-11-22	이뮤노포지 주식회사	글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
KR102119188B1 (ko) *	2018-11-13	2020-06-08	이뮤노포지 주식회사	글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
CA3111178A1 (en) *	2019-02-28	2020-09-03	Nitta Gelatin Inc.	Brain function regulating agent, and food or beverage product containing same
WO2020214012A1 (ko) *	2019-04-19	2020-10-22	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2020214013A1 (ko) *	2019-04-19	2020-10-22	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도
MX2022001975A (es)	2019-08-16	2022-03-11	Applied Molecular Transport Inc	Composiciones, formulaciones y produccion y purificacion de interleucinas.
IL291876A (en)	2019-11-06	2022-06-01	Novo Nordisk As	Receptor agonists in glp-1 type dementia
MX2022008646A (es) *	2020-01-13	2022-08-10	Hanmi Pharm Ind Co Ltd	Uso terapeutico de un conjugado de accion prolongada de un triple agonista que tiene actividad en todos los receptores de glucagon/glp-1/gip para enfermedades pulmonares.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3710795A (en)	1970-09-29	1973-01-16	Alza Corp	Drug-delivery device with stretched, rate-controlling membrane
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CA2137206A1 (en) *	1993-12-09	1995-06-10	John A. Galloway	Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US5574008A (en) *	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
WO1997046584A1 (de)	1996-06-05	1997-12-11	Boehringer Mannheim Gmbh	Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE122007000044I2 (de)	1997-01-07	2011-05-05	Amylin Pharmaceuticals Inc	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US6268479B1 (en) *	1997-03-12	2001-07-31	The Trustees Of Columbia University In The City Of New York	Intracellular amyloid-beta peptide binding (ERAB) polypeptide
EP2583675A1 (de) *	1998-02-02	2013-04-24	Trustees Of Tufts College	Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus
EP1054594B1 (de) *	1998-02-13	2007-07-04	Amylin Pharmaceuticals, Inc.	Inotropische und diuretische effekte von exendin und glp-1
EP1056774A1 (de)	1998-02-27	2000-12-06	Novo Nordisk A/S	N-terminal verkürzte glp-1 derivate
NZ506839A (en)	1998-03-09	2003-05-30	Zealand Pharma As	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE69941510D1 (de)	1998-08-10	2009-11-19	Us Gov Nat Inst Health	Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
MY155270A (en)	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
US6429197B1 (en) *	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
CZ295044B6 (cs) *	1998-12-07	2005-05-18	Societe De Conseils De Recherches Et D'application	Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
EP1992641A3 (de) *	1998-12-07	2009-07-29	Ipsen Pharma	GLP-1-Analoge
JP3136356B2 (ja)	1998-12-15	2001-02-19	農林水産省家畜衛生試験場長	改変型シグナルペプチドをコードするｄｎａ
US6902744B1 (en) *	1999-01-14	2005-06-07	Amylin Pharmaceuticals, Inc.	Exendin agonist formulations and methods of administration thereof
US7396809B1 (en)	1999-02-10	2008-07-08	Curis, Inc.	Methods and reagents for treating glucose metabolic disorders
BR0010750A (pt) *	1999-05-17	2002-02-26	Conjuchem Inc	Peptìdeos insulinotrópicos de longa duração
US6506724B1 (en) *	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1076066A1 (de) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
AU1303301A (en) *	1999-11-10	2001-06-06	Takeda Chemical Industries Ltd.	Body weight gain inhibitors
US6278018B1 (en)	1999-12-14	2001-08-21	Surmodics, Inc.	Surface coating agents
WO2001051078A1 (en) *	2000-01-10	2001-07-19	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
AU2001232337A1 (en) *	2000-02-18	2001-08-27	Kanagawa Academy Of Science And Technology	Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
EP1136071A3 (de) *	2000-03-22	2003-03-26	Pfizer Products Inc.	Verwendung von Glykogen-Phosphorylase-Hemmern
US20020115605A1 (en) *	2000-08-24	2002-08-22	Matthew During	Novel peptide with effects on cerebral health
IL155812A0 (en) *	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
ATE408414T1 (de)	2001-07-31	2008-10-15	Us Gov Health & Human Serv	Glp 1 exendin 4 peptidanaloga und deren verwendungen
CA2485835C (en) *	2002-05-24	2018-03-06	Restoragen, Inc.	Methods and dna constructs for high yield production of polypeptides
US6969702B2 (en) *	2002-11-20	2005-11-29	Neuronova Ab	Compounds and methods for increasing neurogenesis
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US20100003235A1 (en)	2005-09-28	2010-01-07	Hagie Frank E	Oral formulations for enteric disorders and/or rehydration
JP2013007734A (ja)	2011-01-17	2013-01-10	Nippon Dempa Kogyo Co Ltd	外力検出装置及び外力検出センサー

2002
- 2002-07-30 AT AT02748271T patent/ATE408414T1/de not_active IP Right Cessation
- 2002-07-30 WO PCT/US2002/024141 patent/WO2003011892A2/en not_active Ceased
- 2002-07-30 AT AT08162544T patent/ATE536881T1/de active
- 2002-07-30 DE DE60228972T patent/DE60228972D1/de not_active Expired - Lifetime
- 2002-07-30 JP JP2003517083A patent/JP2005501058A/ja not_active Revoked
- 2002-07-30 US US10/485,140 patent/US7576050B2/en not_active Expired - Lifetime
- 2002-07-30 CA CA2455963A patent/CA2455963C/en not_active Expired - Lifetime
- 2002-07-30 EP EP10177860.3A patent/EP2275117B1/de not_active Expired - Lifetime
- 2002-07-30 AU AU2002317599A patent/AU2002317599B2/en not_active Expired
- 2002-07-30 EP EP08162544A patent/EP2022505B1/de not_active Expired - Lifetime
- 2002-07-30 EP EP02748271A patent/EP1411968B1/de not_active Expired - Lifetime
2008
- 2008-07-01 AU AU2008202893A patent/AU2008202893B2/en not_active Expired
- 2008-12-18 US US12/317,042 patent/US8278272B2/en not_active Expired - Fee Related
2009
- 2009-11-18 JP JP2009262568A patent/JP5631578B2/ja not_active Expired - Lifetime
2012
- 2012-08-24 US US13/594,313 patent/US8853160B2/en not_active Expired - Lifetime
2013
- 2013-01-18 JP JP2013007734A patent/JP5695097B2/ja not_active Expired - Lifetime
2014
- 2014-08-27 US US14/470,528 patent/US10941187B2/en active Active

Also Published As

Publication number	Publication date
US20120329715A1 (en)	2012-12-27
EP2022505B1 (de)	2011-12-14
DE60228972D1 (de)	2008-10-30
EP1411968A4 (de)	2005-06-15
US10941187B2 (en)	2021-03-09
AU2002317599B2 (en)	2008-04-03
EP2022505A2 (de)	2009-02-11
EP2275117B1 (de)	2016-10-26
US20040242853A1 (en)	2004-12-02
AU2008202893A1 (en)	2008-07-24
US8853160B2 (en)	2014-10-07
US20150072930A1 (en)	2015-03-12
US8278272B2 (en)	2012-10-02
AU2008202893B2 (en)	2012-01-12
US20090253625A1 (en)	2009-10-08
JP5631578B2 (ja)	2014-11-26
WO2003011892A3 (en)	2004-02-26
US7576050B2 (en)	2009-08-18
EP2022505A3 (de)	2009-05-27
JP2010090129A (ja)	2010-04-22
CA2455963A1 (en)	2003-02-13
ATE536881T1 (de)	2011-12-15
EP2275117A1 (de)	2011-01-19
JP2005501058A (ja)	2005-01-13
JP2013139447A (ja)	2013-07-18
EP1411968B1 (de)	2008-09-17
WO2003011892A2 (en)	2003-02-13
EP1411968A2 (de)	2004-04-28
JP5695097B2 (ja)	2015-04-01
CA2455963C (en)	2017-07-04

Legal Events

Date	Code	Title	Description
2009-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties
2010-10-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE408414T1 (de)	2008-10-15	Glp 1 exendin 4 peptidanaloga und deren verwendungen
DK0699686T3 (da)	2004-02-16	Biologisk aktive fragmenter af glukagon-lignende insulinotropisk peptid
EA200100289A1 (ru)	2001-10-22	Способ введения инсулинотропных пептидов
DK1294757T3 (da)	2007-03-19	Glucagonlignende peptid 1-analoger
DE60134251D1 (de)	2008-07-10	Verwendung von glp-2-peptiden
ATE480259T1 (de)	2010-09-15	Intranasale verabreichung von glucose- regulierenden peptiden
BR9401185A (pt)	1994-10-18	Processo para o tratamento de diabetes mellitus e composição de matéria
ATE394423T1 (de)	2008-05-15	Analoge des glucagon ähnlichen peptides-1 (glp-1)
EP0464022A4 (en)	1992-04-15	Insulinotropic hormone
ATE187647T1 (de)	2000-01-15	Verwendung eines peptids
DK0733644T3 (da)	2004-08-16	Glucagonlignende, insulinotrope komplekser, sammensætninger og fremgangsmåder
DK1638586T3 (da)	2008-06-23	Synergistisk sammensætning til behandling af diabetes mellitus
DE69942307D1 (de)	2010-06-10	N-terminal veränderte glp-1 abkömmlinge
WO2003018516A3 (en)	2004-02-26	Glucagon-like peptide-1 analogs
DK0762890T3 (da)	2000-11-13	Behandling af diabetes
DK1751184T3 (da)	2009-11-23	FGF-21 fusionsproteiner
ECSP993116A (es)	1999-11-29	Procedimiento para administrar peptidos insulinotropicos